News | August 10, 2025
Aurobindo Pharma Q1 FY26 PAT slips 10% YoY to Rs. 824 Cr
Aurobindo Pharma’s US formulations revenue slipped 1.9% on a year-on-year basis to Rs. 3,488 crore
Aurobindo Pharma’s US formulations revenue slipped 1.9% on a year-on-year basis to Rs. 3,488 crore
The Q-Switched Nd:YAG system is suitable for all skin types and offers versatility in treating dermal and epidermal pigmentation
The operating profit (EBITDA) rose 20.7% to Rs. 156.4 crore
The company reported a 28% year-on-year increase in Q2 revenue to Rs. 220.9 crore
The facility includes advanced laboratories to monitor market trends, consumer needs, product innovation, and formulation improvements
A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
Novartis India has reported total income of Rs. 98.16 crores during the period ended June 30, 2025
Sigachi Industries has reported total income of Rs. 132.18 crores during the period ended June 30, 2025
Subscribe To Our Newsletter & Stay Updated
